Nahdi Medical Valuation
Is 4164 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4164 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4164 (SAR133.8) is trading above our estimate of fair value (SAR131.28)
Significantly Below Fair Value: 4164 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4164?
Other financial metrics that can be useful for relative valuation.
What is 4164's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ر.س17.45b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2x |
Enterprise Value/EBITDA | 15x |
PEG Ratio | 2.5x |
Price to Earnings Ratio vs Peers
How does 4164's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 27.8x | ||
4163 Al-Dawaa Medical Services | 22.9x | 14.3% | ر.س8.0b |
4001 Abdullah Al-Othaim Markets | 23.3x | 7.7% | ر.س11.4b |
4161 BinDawood Holding | 38.1x | 8.7% | ر.س10.5b |
4162 Almunajem Foods | 27.1x | n/a | ر.س7.6b |
4164 Nahdi Medical | 19.5x | 7.7% | ر.س17.4b |
Price-To-Earnings vs Peers: 4164 is good value based on its Price-To-Earnings Ratio (19.5x) compared to the peer average (27.8x).
Price to Earnings Ratio vs Industry
How does 4164's PE Ratio compare vs other companies in the Asian Consumer Retailing Industry?
Price-To-Earnings vs Industry: 4164 is expensive based on its Price-To-Earnings Ratio (19.5x) compared to the Asian Consumer Retailing industry average (17.7x).
Price to Earnings Ratio vs Fair Ratio
What is 4164's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 19.5x |
Fair PE Ratio | 30.1x |
Price-To-Earnings vs Fair Ratio: 4164 is good value based on its Price-To-Earnings Ratio (19.5x) compared to the estimated Fair Price-To-Earnings Ratio (30.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | ر.س133.80 | ر.س155.44 +16.2% | 8.1% | ر.س176.00 | ر.س134.00 | n/a | 7 |
May ’25 | ر.س137.40 | ر.س155.44 +13.1% | 8.1% | ر.س176.00 | ر.س134.00 | n/a | 7 |
Apr ’25 | ر.س146.20 | ر.س156.01 +6.7% | 8.8% | ر.س176.00 | ر.س134.00 | n/a | 7 |
Mar ’25 | ر.س142.00 | ر.س155.37 +9.4% | 9.5% | ر.س176.00 | ر.س134.00 | n/a | 6 |
Feb ’25 | ر.س139.20 | ر.س155.37 +11.6% | 9.5% | ر.س176.00 | ر.س134.00 | n/a | 6 |
Jan ’25 | ر.س143.00 | ر.س159.53 +11.6% | 12.3% | ر.س190.00 | ر.س134.00 | n/a | 6 |
Dec ’24 | ر.س135.80 | ر.س164.60 +21.2% | 11.4% | ر.س190.00 | ر.س134.00 | n/a | 5 |
Nov ’24 | ر.س134.40 | ر.س176.40 +31.3% | 14.9% | ر.س221.00 | ر.س148.00 | n/a | 5 |
Oct ’24 | ر.س146.60 | ر.س176.40 +20.3% | 14.9% | ر.س221.00 | ر.س148.00 | n/a | 5 |
Sep ’24 | ر.س151.80 | ر.س187.25 +23.4% | 13.9% | ر.س221.00 | ر.س148.00 | n/a | 4 |
Aug ’24 | ر.س176.00 | ر.س203.60 +15.7% | 7.8% | ر.س221.00 | ر.س180.00 | n/a | 5 |
Jul ’24 | n/a | ر.س203.60 0% | 7.8% | ر.س221.00 | ر.س180.00 | n/a | 5 |
Jun ’24 | ر.س171.60 | ر.س203.60 +18.6% | 7.8% | ر.س221.00 | ر.س180.00 | n/a | 5 |
May ’24 | ر.س181.20 | ر.س207.00 +14.2% | 7.7% | ر.س221.00 | ر.س180.00 | ر.س137.40 | 4 |
Apr ’24 | ر.س184.60 | ر.س216.00 +17.0% | 1.7% | ر.س221.00 | ر.س212.00 | ر.س146.20 | 3 |
Mar ’24 | ر.س181.00 | ر.س209.33 +15.7% | 2.9% | ر.س215.00 | ر.س201.00 | ر.س142.00 | 3 |
Feb ’24 | ر.س187.80 | ر.س209.33 +11.5% | 2.9% | ر.س215.00 | ر.س201.00 | ر.س139.20 | 3 |
Jan ’24 | ر.س171.60 | ر.س210.00 +22.4% | 4.3% | ر.س219.00 | ر.س201.00 | ر.س143.00 | 2 |
Dec ’23 | ر.س187.80 | ر.س186.67 -0.6% | 13.4% | ر.س219.00 | ر.س158.00 | ر.س135.80 | 3 |
Nov ’23 | ر.س198.40 | ر.س186.67 -5.9% | 13.4% | ر.س219.00 | ر.س158.00 | ر.س134.40 | 3 |
Oct ’23 | ر.س189.80 | ر.س186.67 -1.7% | 13.4% | ر.س219.00 | ر.س158.00 | ر.س146.60 | 3 |
Sep ’23 | ر.س194.00 | ر.س182.67 -5.8% | 11.0% | ر.س207.00 | ر.س158.00 | ر.س151.80 | 3 |
Aug ’23 | ر.س182.00 | ر.س182.67 +0.4% | 11.0% | ر.س207.00 | ر.س158.00 | ر.س176.00 | 3 |
Jul ’23 | ر.س161.80 | ر.س182.67 +12.9% | 11.0% | ر.س207.00 | ر.س158.00 | n/a | 3 |
Jun ’23 | ر.س160.00 | ر.س170.50 +6.6% | 7.3% | ر.س183.00 | ر.س158.00 | ر.س171.60 | 2 |
Analyst Forecast: Target price is less than 20% higher than the current share price.